(Press-News.org) MINNEAPOLIS – A new drug may bring help for people with insomnia, according to a study published in the November 28, 2012, online issue of Neurology®, the medical journal of the American Academy of Neurology.
The drug, suvorexant, blocks the chemical messengers in the brain called orexins, which regulate wakefulness. Other drugs for insomnia affect different brain receptors.
Taking the drug suvorexant increased the amount of time people spent asleep during the night, according to the study. The study involved 254 people ages 18 to 64 who were in good physical and mental health but had insomnia that was not due to another medical condition.
The participants took either the drug or a placebo for four weeks, then switched to the other treatment for another four weeks. The participants spent the night in a sleep laboratory with their sleep monitored on the first night with each treatment and then again in the fourth week of each treatment.
While taking the drug, participants' "sleep efficiency," which reflects the total amount of time they slept during a fixed, eight hour time in bed, improved by 5 to 13 percent compared to those taking the placebo. They also experienced 21 to 37 fewer minutes awake during the night after they had fallen asleep than those who took the placebo.
"This study provides evidence that suvorexant may offer a successful alternative strategy for treating insomnia," said study author W. Joseph Herring, MD, PhD, of North Wales, Penn., Executive Director of Clinical Research with Merck, the maker of suvorexant, and a member of the American Academy of Neurology. "Suvorexant was generally well-tolerated, and there were no serious side effects."
Herring said larger, longer studies have recently been conducted on suvorexant, along with studies to determine whether the drug could be safe and effective for elderly people, who make up a large percentage of those suffering from insomnia.
###
Merck has submitted a new drug application for the treatment with the U. S. Food and Drug Administration.
The study was funded by Merck Research Laboratories.
To learn more about insomnia and other sleep disorders, visit http://www.aan.com/patients.
The American Academy of Neurology, an association of more than 25,000 neurologists and neuroscience professionals, is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as Alzheimer's disease, stroke, migraine, multiple sclerosis, brain injury, Parkinson's disease and epilepsy.
For more information about the American Academy of Neurology, visit http://www.aan.com or find us on Facebook, Twitter, Google+ and YouTube.
Media Contacts:
Rachel Seroka, rseroka@aan.com, (612) 928-6129
Angela Babb, APR, ababb@aan.com, (612) 928-6102
Drug may offer new approach to treating insomnia
2012-11-29
ELSE PRESS RELEASES FROM THIS DATE:
Tiny algae shed light on photosynthesis as a dynamic property
2012-11-29
One of the first chemical reactions children learn is the recipe for photosynthesis, combining carbon dioxide, water and solar energy to produce organic compounds. Many of the world's most important photosynthetic eukaryotes such as plants did not develop the ability to combine these ingredients themselves. Rather, they got their light-harnessing organelles -- chloroplasts -- indirectly by stealing them from other organisms. In some instances, this has resulted in algae with multiple, distinct genomes, the evolutionary equivalent of a "turducken*."
Chloroplasts originally ...
Morality-based judgments are quicker, more extreme than practical evaluations
2012-11-29
Judgments made after a moral evaluation are quicker and more extreme than the same judgment based on practical considerations, but morality-based evaluations can be more easily shifted and made with other considerations in mind, according to research published November 28 in the open access journal PLOS ONE by Jay Van Bavel and colleagues from New York University.
Previous research has suggested that moral reasoning usually occurs after a person makes a decision, as a post hoc justification of their choice, rather than the basis for the decision itself. This new study ...
More omnivore dilemmas: Seasonal diet changes can cause reproductive stress in primates
2012-11-29
When seasonal changes affect food availability, omnivores like blue monkeys adapt by changing their diets, but such nutritional changes may impact female reproduction, according to research published November 28 in the open access journal PLOS ONE by Steffen Foerster from Barnard College, and colleagues from Columbia University and the Smithsonian Institution.
The authors found that levels of fecal glucocorticoids (fGC), a stress marker, increased when female monkeys shifted their diet towards lower quality fallback foods, whereas the levels decreased when the monkeys ...
Skeletons in cave reveal Mediterranean secrets
2012-11-29
Skeletal remains in an island cave in Favignana, Italy, reveal that modern humans first settled in Sicily around the time of the last ice age and despite living on Mediterranean islands, ate little seafood. The research is published November 28 in the open access journal PLOS ONE by Marcello Mannino and colleagues from the Max Planck Institute for Evolutionary Anthropology, Germany.
Genetic analysis of the bones discovered in caves on the Egadi islands provides some of the first mitochondrial DNA data available for early humans from the Mediterranean region, a crucial ...
Scientists identify depression and anxiety biomarker in youths
2012-11-29
Scientists have discovered a cognitive biomarker – a biological indicator of a disease – for young adolescents who are at high risk of developing depression and anxiety. Their findings were published today, 28 November, in the journal PLOS ONE.
The test for the unique cognitive biomarker, which can be done on a computer, could be used as an inexpensive tool to screen adolescents for common emotional mental illnesses. As the cognitive biomarker may appear prior to the symptoms of depression and anxiety, early intervention (which has proven to be one of the most effective ...
Chemists invent powerful toolkit, accelerating creation of potential new drugs
2012-11-29
LA JOLLA, CA – Scientists at The Scripps Research Institute (TSRI) have invented a set of chemical tools that is radically simplifying the creation of potential new drug compounds.
Pharmaceutical chemists frequently seek to generate dozens or even hundreds of variations of a given compound to see which works best. The new toolkit—described in the November 28, 2012 issue of the journal Nature—makes this process easier and cheaper, enabling previously time- and cost-prohibitive chemical modifications. This fundamental innovation is already being adopted by drug companies ...
New studies show moral judgments quicker, more extreme than practical ones -- but also flexible
2012-11-29
Judgments we make with a moral underpinning are made more quickly and are more extreme than those same judgments based on practical considerations, a new set of studies finds. However, the findings, which appear in the journal PLOS ONE, also show that judgments based on morality can be readily shifted and made with other considerations in mind.
"Little work has been done on how attaching morality to a particular judgment or decision may affect that outcome," explains Jay Van Bavel, an assistant professor in New York University's Department of Psychology and one of the ...
KRAS and BRAF mutation screening in metastatic colorectal cancer costly in relation to benefits
2012-11-29
Researchers report that screening for KRAS and BRAF mutations can reduce the cost of anti-EGFR treatment for metastatic colorectal cancer but with a very small reduction in overall survival according to a new study published on November 28 in the Journal of the National Cancer Institute.
Metastatic colorectal cancer patients whose tumors harbor mutations in KRAS (and to a lesser extent, in BRAF) are unlikely to respond to costly anti-EGFR therapies. Screening of patients who are candidates for these therapies for mutations in one of these genes (KRAS) has been recommended, ...
NSAID use linked to reduced hepatocellular carcinoma risk and mortality due to chronic liver disease
2012-11-29
Researchers found that aspirin use is associated with a decreased risk of developing hepatocellular carcinoma and death from chronic liver disease (CLD), according to a study published November 28 in the Journal of the National Cancer Institute.
Hepatocellular carcinoma (HCC), the most common type of primary liver cancer, occurs mainly among patients with CLD. Previous reports have linked chronic inflammation due to CLD to cellular processes that could promote carcinogenesis. Because of their anti-inflammatory properties and widespread use to prevent cardiovascular and ...
Combined RB and PTEN loss identifies DCIS primed for invasive breast cancer
2012-11-29
The combined loss of two tumor suppressor genes, retinoblastoma (RB) and phosphatase and tensin homolog (PTEN) was shown to be strongly associated with progression of DCIS to invasive breast cancer, according to a study published November 28 in the Journal of the National Cancer Institute.
Ductal carcinoma in situ (DCIS) is a breast cancer precursor lesion for which there are no established markers defining risk of progression to invasive breast cancer. As a result, the majority of women are treated uniformly with surgery and radiation therapy potentially with additional ...